This review aimed to comprehensively summarize the most recent findings regarding the pharmacogenetics of the biologics anti-TNF-α (IFX and ADA), UST, and VDZ in IBD to shed light on the genetic variants that affect the clinical response to biologics. The gene discussed is ADA; the disease is inflammatory bowel disease.